Research firm Markets Research officially released the 11th edition of its Small Molecule Drug Discovery Market report on October 26, 2017. This report shows the market share of key players and market dynamics, noting that the Global drug discovery market is expected to grow significantly over the long run. Additionally, the report provides a detailed forecast of marketed drugs by region, title, molecule type, and application area. Many small molecule drugs are used successfully to treat people with diseases such as cancer and Parkinson’s disease because the drug is a unique drug for the person. To create this particular molecule, scientists found that the atoms in a chemical structure worked the same way as a protein receptor. This can be extremely time consuming and expensive for some businesses. A startup has developed a new way for computer software to design these molecules quickly and cheaply using input from thousands of tiny molecules.

introduction

The US drug discovery market includes a growing number of small molecule drugs to treat chronic and rare diseases. Over the past five years, this market has been estimated to grow from around $36 billion worldwide in 2005 to $170 billion by 2023. Because the industry is highly fragmented and fragmented according to many different dimensions, it is not surprising that several different definitions attempt to describe what constitutes a small molecular drug. This report will review the history of small molecule drug discovery in academic institutions, small molecules and their patents, current strategies of companies involved in small molecule drug discovery, benefits and risks in pharmaceutical companies , public policies on the restriction of small molecules.

Click on the tab below to avail the sample copy of the report [email protected]

Sample request

Market driving forces

The Small Molecule Drug Discovery Market report analyzes the emerging market for drug discovery and preclinical research services between 2012 and 2022. The global healthcare market is expected to reach USD 36.71 billion by 2022, with a growth rate annual compound (CAGR) of 6% over the next eight years. Factors that should drive this growth potential include:
An aging population.
Increase in cases of chronic diseases.
Growing demand for affordable drugs.
Increasing availability of data from government sources in countries with restricted access to health insurance schemes.

Global Small Molecule Drug Discovery Market Analysis and Forecast 2019

Silicon Labs International Inc. (“Silicon Labs”, “San Jose, CA”), a global semiconductor company that produces sensors and microcontrollers, provides a comprehensive report on global semiconductor market analysis and forecasts. small molecule drug discovery 2019. Silicon Labs uses data-driven technology to provide comprehensive insights into drug discovery markets including antibiotics, cancer treatments, CNS and respiratory treatments, cardiovascular therapies and vaccines.

Key players operating in the world of drug discovery

The companies profiled in the article are Roche, Takeda Pharmaceuticals, Eli Lilly and Company, Merck & Co., Johnson & Johnson, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd., AstraZeneca PLC and Sanofi SA. The small molecule drug discovery market is growing owing to the advancement in technologies and the improvement of major players in the industry. A few key players have established various platforms for discovering drug targets and synthesizing small molecules, resulting in huge success in helping companies generate new pipelines, assess potential, and understand new mechanisms of action.

Click on the tab below for the instant purchase of the report with a flat rate discount of $500

Instant Buy Request

Lack of New Human Drugs Could Increase North America Ligand Aptamer Market Size in 2027

The lack of new drugs for human use from big pharmaceutical companies could open the market to other classes of drugs. Aptamers are self-contained molecules and could be used as oncology-specific drugs for the treatment of cancer. As a result, the market size is estimated at $255 million. Such a phenomenon will increase the number of Ligand aptamers in North America, allowing these companies to focus more on research and development.